Literature DB >> 18674839

Factors responsible for elevation of 1-h postchallenge plasma glucose levels in Japanese men.

Norio Harada1, Mitsuo Fukushima, Kentaro Toyoda, Rie Mitsui, Tomoyo Izuka, Ataru Taniguchi, Yoshikatsu Nakai, Yuichiro Yamada, Yutaka Seino, Nobuya Inagaki.   

Abstract

The 1-h postchallenge plasma glucose (1-h PG) level is considered to be a good index of the development of glucose intolerance and type 2 diabetes as well as of diabetic complications. In some cases, in Japanese, 1-h PG is elevated despite normal fasting glucose during oral glucose tolerance test (OGTT), but the factors responsible remain unclear. In the present study, subjects with normal glucose tolerance (NGT), isolated impaired fasting glucose (IFG), and isolated impaired glucose tolerance (IGT) were divided into subgroups at 1-h PG of 10.0mM, and the four indices of insulin secretion and insulin sensitivity were compared. In all three categories, the insulinogenic index in subjects with elevated 1-h PG was remarkably lower than in those without elevated 1-h PG. In addition, the insulinogenic index was the strongest factor in elevated 1-h PG according to the multiple regression analysis. Interestingly, one third of the NGT subjects enrolled in this study had elevated 1-h PG. These subjects showed significantly elevated area under the curve of glucose (G-AUC) compared to NGT subjects without 1-h PG elevation. Thus, elevated 1-h PG in Japanese subjects indicates mildly impaired glucose tolerance due to decreased early-phase insulin secretion.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18674839     DOI: 10.1016/j.diabres.2008.04.011

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  6 in total

1.  The correlation between the oral glucose tolerance test 30-minutes plasma glucose and risk factors for diabetes and cardiovascular diseases: a cross-sectional epidemiological study of diabetes in Fujian Province in the South-East of China.

Authors:  G Chen; X Zou; J Yao; Q Jiang; Y Zhang; M Tu; S Yang; S Xu; W Lin; H Huang; J Liang; L Li; L Lin
Journal:  J Endocrinol Invest       Date:  2010-10-08       Impact factor: 4.256

2.  Insulin secretory capacity and insulin sensitivity in impaired fasting glucose in Japanese.

Authors:  Rie Mitsui; Mitsuo Fukushima; Ataru Taniguchi; Yoshikatsu Nakai; Sae Aoyama; Yoshitaka Takahashi; Hideaki Tsuji; Daisuke Yabe; Koichiro Yasuda; Takeshi Kurose; Toshiko Kawakita; Yutaka Seino; Nobuya Inagaki
Journal:  J Diabetes Investig       Date:  2012-08-20       Impact factor: 4.232

3.  Plasma gastric inhibitory polypeptide and glucagon-like peptide-1 levels after glucose loading are associated with different factors in Japanese subjects.

Authors:  Norio Harada; Akihiro Hamasaki; Shunsuke Yamane; Atsushi Muraoka; Erina Joo; Kazuyo Fujita; Nobuya Inagaki
Journal:  J Diabetes Investig       Date:  2011-06-05       Impact factor: 4.232

4.  Effects of glucose and meal ingestion on incretin secretion in Japanese subjects with normal glucose tolerance.

Authors:  Shunsuke Yamane; Norio Harada; Akihiro Hamasaki; Atsushi Muraoka; Erina Joo; Kazuyo Suzuki; Daniela Nasteska; Daisuke Tanaka; Masahito Ogura; Shin-Ichi Harashima; Nobuya Inagaki
Journal:  J Diabetes Investig       Date:  2012-02-20       Impact factor: 4.232

5.  Synergistic Effects of 1 h Post-Load Plasma Glucose and Smoking on Arterial Stiffness in Apparently Healthy Men: A Cross-sectional Study.

Authors:  Atsushi Nakagomi; Yuko Sunami; Sho Okada; Takehiko Fujisawa; Yoshio Kobayashi
Journal:  J Atheroscler Thromb       Date:  2018-11-17       Impact factor: 4.928

6.  Effect of Lactobacillus casei strain Shirota-fermented milk on metabolic abnormalities in obese prediabetic Japanese men: a randomised, double-blind, placebo-controlled trial.

Authors:  Eiichiro Naito; Yasuto Yoshida; Satoru Kunihiro; Kumiko Makino; Kohei Kasahara; Yuu Kounoshi; Masanori Aida; Ryotaro Hoshi; Osamu Watanabe; Tomoki Igarashi; Kouji Miyazaki; Hideki Ito
Journal:  Biosci Microbiota Food Health       Date:  2017-09-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.